*Table 14-3.03*
*ADAS Cog (11) - Change from Baseline to Week 8 - LOCF*

|  | Placebo (N=79) | Xanomeline Low Dose (N=81) | Xanomeline High Dose (N=74) |
|---|---|---|---|
| Baseline |  |  |  |
|   n | 79 | 81 | 74 |
|   Mean (SD) | 24.1 (12.19) | 24.4 (12.92) | 21.3 (11.74) |
|   Median (Range) | 21.0 (5;61) | 21.0 (5;57) | 18.0 (3;57) |
| Week 8 |  |  |  |
|   n | 79 | 81 | 74 |
|   Mean (SD) | 25.0 (13.10) | 26.2 (12.98) | 22.3 (12.41) |
|   Median (Range) | 22.0 (5;62) | 25.0 (5;62) | 19.0 (2;62) |
| Change from Baseline |  |  |  |
|   n | 79 | 81 | 74 |
|   Mean (SD) | 0.8 (4.81) | 1.8 (4.14) | 1.0 (3.62) |
|   Median (Range) | 1.0 (-12;16) | 2.0 (-12;14) | 1.0 (-8;13) |
|  |  |  |  |
| p-value(Dose Response) [1][2] |  |  | 0.497 |
|  |  |  |  |
| p-value(Xan - Placebo) [1][3] |  | 0.099 | 0.751 |
|  Diff of LS Means (SE) |  | 1.1 (0.65) | 0.2 (0.67) |
|  95% CI |  | (-0.2;2.4) | (-1.1;1.5) |
|  |  |  |  |
| p-value(Xan High - Xan Low) [1][3] |  |  | 0.195 |
|  Diff of LS Means (SE) |  |  | -0.9 (0.66) |
|  95% CI |  |  | (-2.2;0.4) |

[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline value as a covariate.
[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable.
[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.